Oasmia Pharmaceutical – executive interview

Oasmia Pharmaceutical – executive interview

Vivesto — 3 videos in collection

Oasmia Pharmaceutical is a specialty pharmaceutical company focused on developing new therapeutic options for patients suffering from hard-to-treat cancers. Oasmia has an emerging pipeline of clinical-stage assets targeting late-stage cancers. Apealea (paclitaxel micellar) is commercialised for ovarian cancer patients through a partnership with Elevar Therapeutics. Development programmes include Cantrixil, which is in clinical development for late-stage ovarian cancer, and Docetaxel micellar, which is in development for advanced prostate cancer.

In this interview, Oasmia’s CEO, Francois Martelet, discusses the company’s recent issue of shares with preferential rights for existing shareholders of approximately SEK151m, subject to approval at an extraordinary general meeting to be held on 21 February 2022.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.